MA56397A - Protéines de liaison à l'il1rap - Google Patents

Protéines de liaison à l'il1rap

Info

Publication number
MA56397A
MA56397A MA056397A MA56397A MA56397A MA 56397 A MA56397 A MA 56397A MA 056397 A MA056397 A MA 056397A MA 56397 A MA56397 A MA 56397A MA 56397 A MA56397 A MA 56397A
Authority
MA
Morocco
Prior art keywords
binding proteins
il1rap binding
il1rap
proteins
binding
Prior art date
Application number
MA056397A
Other languages
English (en)
Inventor
John G Emery
Qi Fei
Shiyong Gong
Sanjay Kumar
Fang Ren
Teddy Yang
Hua Ying
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA56397A publication Critical patent/MA56397A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA056397A 2019-06-26 2020-06-22 Protéines de liaison à l'il1rap MA56397A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019093114 2019-06-26

Publications (1)

Publication Number Publication Date
MA56397A true MA56397A (fr) 2022-05-04

Family

ID=71738216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056397A MA56397A (fr) 2019-06-26 2020-06-22 Protéines de liaison à l'il1rap

Country Status (12)

Country Link
US (1) US20230295313A1 (fr)
EP (1) EP3990494A1 (fr)
JP (1) JP2022539178A (fr)
KR (1) KR20220026585A (fr)
CN (1) CN114222760A (fr)
AU (1) AU2020308053A1 (fr)
BR (1) BR112021025476A2 (fr)
CA (1) CA3143211A1 (fr)
IL (1) IL289145A (fr)
MA (1) MA56397A (fr)
MX (1) MX2021015651A (fr)
WO (1) WO2020261097A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170008A2 (fr) * 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anticorps anti-il1rap
US20220411517A1 (en) 2021-05-21 2022-12-29 Leo Pharma A/S IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof
CA3226673A1 (fr) * 2021-07-21 2023-01-21 Stelexis Therapeutics, Llc Anticorps il1rap et utilisations connexes
CN116041503A (zh) * 2022-10-31 2023-05-02 江汉大学 一种fam50a蛋白多克隆抗体及其制备方法与应用
CN116574189A (zh) * 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations
WO2025209480A1 (fr) * 2024-04-02 2025-10-09 福佑泰生物制药公司 Anticorps anti-il1rap et son utilisation
WO2026022232A1 (fr) 2024-07-24 2026-01-29 Almirall, S.A. Inhibiteur d'il-1rap pour le traitement ou la prévention de l'hidradénite suppurée

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1176195B1 (fr) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE395923T1 (de) 2000-05-19 2008-06-15 Corixa Corp Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
EP1311522B1 (fr) 2000-08-04 2006-03-22 Corixa Corporation Nouveaux composes immuno-effecteurs
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP1921090B1 (fr) 2005-07-22 2015-01-14 Kyowa Hakko Kirin Co., Ltd. Composition d'anticorps genetiquement modifie
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
HUE032735T2 (en) 2007-12-14 2017-10-30 Bristol Myers Squibb Co Binding molecules for the human OX40 receptor
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
WO2011042548A1 (fr) * 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides de liaison au « récepteur de produits terminaux de glycation avancée » ainsi que compositions et procédés les mettant en jeu
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
PL2609118T3 (pl) 2010-08-23 2017-07-31 Board Of Regents, The University Of Texas System Przeciwciała anty-OX40 i sposoby ich stosowania
RU2597831C2 (ru) * 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
KR101685262B1 (ko) 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
CA2886433C (fr) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
CN107001471B (zh) * 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
CA2990305A1 (fr) * 2015-06-26 2016-12-29 Mab Discovery Gmbh Anticorps monoclonaux anti-il-1racp
MA43164A (fr) * 2015-11-02 2018-09-12 Janssen Pharmaceutica Nv Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
WO2018071910A2 (fr) * 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anticorps anti-il1-rap
JP7657440B2 (ja) * 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート

Also Published As

Publication number Publication date
US20230295313A1 (en) 2023-09-21
IL289145A (en) 2022-02-01
KR20220026585A (ko) 2022-03-04
MX2021015651A (es) 2022-06-14
EP3990494A1 (fr) 2022-05-04
WO2020261097A1 (fr) 2020-12-30
AU2020308053A1 (en) 2022-01-20
BR112021025476A2 (pt) 2022-10-11
JP2022539178A (ja) 2022-09-07
CN114222760A (zh) 2022-03-22
CA3143211A1 (fr) 2020-12-30

Similar Documents

Publication Publication Date Title
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
MA56397A (fr) Protéines de liaison à l'il1rap
EP3717505A4 (fr) Protéines de liaison à l'adn modifiées
EP3694871A4 (fr) Protéines de liaison à l'antigène de maturation de cellules b
MA54513A (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
EP3655432A4 (fr) Protéines de liaison 1
EP4058484A4 (fr) Protéines de liaison à l'antigène ciblant des néoantigènes partagés
EP3668539A4 (fr) Protéines de liaison d'antigène ciblant des antigènes partagés
EP3802581A4 (fr) Protéines de liaison multispécifiques et améliorations de celles-ci
EP3870223A4 (fr) Molécules de liaison à base d'igm et d'iga-fc multivalentes
MA49270A (fr) Récepteurs de liaison à l'antigène améliorés
MA50613A (fr) Molécules de liaison spécifique à l'hpv
MA43874A (fr) Constructions de liaison à l'antigène immunomodulateur multispécifique
EP3635013A4 (fr) Protéines de liaison à la nectine-4 et leurs procédés d'utilisation
MA52182A (fr) Molécules de liaison à l'antigène ciblant her2 comprenant 4-1bbl
EP3641762A4 (fr) Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
EP3299383A4 (fr) MODIFICATION SPÉCIFIQUE DE L'ANTICORPS PAR UN PEPTIDE DE LIAISON À IgG
EP3493844A4 (fr) Protéine de liaison à l'albumine sérique à domaine unique
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
EP3902838A4 (fr) Fractions de liaison à cd30, récepteurs d'antigènes chimériques et leurs utilisations
EP3802551A4 (fr) Inhibiteurs de protéine de liaison à la pénicilline
EP3976624A4 (fr) Inhibiteur de protéine kinase dépendante de l'adn
IL285626A (en) Claudin 6 antibodies and uses thereof
EP3408400A4 (fr) Protéines de liaison à l'antigène se liant à pd-l1
EP3708667A4 (fr) Protéine de liaison à l'immunoglobuline